DeepMed Research

National Cancer Center Korea

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Subsidiary

Established: 1989-01-01

Employees: -

Market Cap: -

Website: http://www.ncc.re.kr

Clinical Trials

A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker

Phase 2

Recruiting

Conditions: Lazertinib

Interventions: Drug: Lazertinib
Drug: Bevacizumab Injectable Product

First Posted Date: 2023-12-05

Last Posted Date: 2023-12-05

Lead Sponsor: National Cancer Center, Korea

Target Recruit Count: 120

Registration Number: NCT06156527

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
🇰🇷
AJOU university hospital, Suwon-si, Gyeunggi-do, Korea, Republic of
🇰🇷
National Cancer Center, Goyang-si, Gyeunggi-do, Korea, Republic of

and more 2 locations

Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers

Phase 2

Not yet recruiting

Conditions: Unresectable Biliary Tract Carcinoma
Unresectable Bile Duct Carcinoma
Unresectable Pancreatic Cancer

Interventions: Drug: Tripegfilgrastim

First Posted Date: 2023-11-18

Last Posted Date: 2023-11-18

Lead Sponsor: National Cancer Center, Korea

Target Recruit Count: 98

Registration Number: NCT06135896

Locations: 🇰🇷
NATIONAL CANCER CENTER 323, Ilsan-ro, Ilsandong-gu,, Goyang-si, Gyeonggi-do, Korea, Republic of

Development of Asian Consortium for Data Collection and Clinical Trial of CNS Tumors

Recruiting

Conditions: Asian Consortium
CNS Germinoma
CNS Tumor

First Posted Date: 2023-08-08

Last Posted Date: 2023-08-08

Lead Sponsor: National Cancer Center, Korea

Target Recruit Count: 400

Registration Number: NCT05982691

Locations: 🇰🇷
National Cancer Center, Korea, Goyang-si, Gyeonggi-do, Korea, Republic of

Feasibility Study of Sentinel Navigation Surgery in Early Gastric Cancer Using Fluorescence (SENORITA4)

Not Applicable

Not yet recruiting

Conditions: Early Gastric Cancer

Interventions: Procedure: Laparoscopic sentinel navigation surgery using fluorescence

First Posted Date: 2023-08-07

Last Posted Date: 2023-08-07

Lead Sponsor: National Cancer Center, Korea

Target Recruit Count: 203

Registration Number: NCT05978882

Locations: 🇰🇷
Dongnam Inst. of Radiological & Medical Science, Busan, Gijang-gun, Korea, Republic of
🇰🇷
Gyeongsang National University Hospital, Gyeongsang, Gingu-si, Korea, Republic of
🇰🇷
Sevrance Hospital, Seoul, Sinchon, Korea, Republic of

and more 4 locations

Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer

Phase 3

Recruiting

Conditions: Ovarian Cancer

Interventions: Drug: Cisplatin

First Posted Date: 2023-04-25

Last Posted Date: 2025-01-31

Lead Sponsor: National Cancer Center, Korea

Target Recruit Count: 520

Registration Number: NCT05827523

Locations: 🇰🇷
National Cancer Center, Goyang, Gyeonggi, Korea, Republic of

CKD-702 Plus Irinotecan in Gastric Cancer

Phase 2

Recruiting

Conditions: Gastric Cancer

Interventions: Drug: CKD-702 in combination with irinotecan

First Posted Date: 2023-03-01

Last Posted Date: 2023-03-01

Lead Sponsor: National Cancer Center, Korea

Target Recruit Count: 40

Registration Number: NCT05750290

Locations: 🇰🇷
National Cancer Center, Goyang, Gyeonggi, Korea, Republic of

Life Style Modification for Breast Canccer Survivors Using Mobile App-based Human Coaching Program

Completed

Conditions: Breast Cancer Survivors

Interventions: Other: mobile application program with human coach

First Posted Date: 2022-08-18

Last Posted Date: 2022-08-18

Lead Sponsor: National Cancer Center, Korea

Target Recruit Count: 130

Registration Number: NCT05506189

Locations: 🇰🇷
National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of

CRS & HIPEC for Platinum-Resistant Recurrent Ovarian Cancer (KOV-02R, RECOVER)

Phase 3

Recruiting

Conditions: Epithelial Ovarian Cancer
Platinum Resistant
Recurrent Ovarian
HIPEC
Mitomycin
Cytoreductive Surgery

Interventions: Procedure: HIPEC

First Posted Date: 2022-04-07

Last Posted Date: 2025-01-31

Lead Sponsor: National Cancer Center, Korea

Target Recruit Count: 140

Registration Number: NCT05316181

Locations: 🇰🇷
Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of
🇰🇷
Korea University Anam hospital, Seoul, Korea, Republic of
🇰🇷
Myong Cheol Lim, Goyang-si, Gyeonggi-do, Korea, Republic of

Brentuximab Vedotin Plus DHAP in Relapsed or Refractory Hodgkin's Lymphoma

Phase 2

Recruiting

Conditions: Relapsed/Refractory Classical Hodgkin Lymphoma

Interventions: Drug: Brentuximab vedotin

First Posted Date: 2022-02-17

Last Posted Date: 2022-02-17

Lead Sponsor: National Cancer Center, Korea

Target Recruit Count: 30

Registration Number: NCT05243693

Locations: 🇰🇷
Hyeon-Seok Eom, Goyang, Gyeonggi-do, Korea, Republic of

Local and Regional Radiotherapy for Nipple Sparing Mastectomy With Implant

Conditions: Breast Cancer

First Posted Date: 2022-01-28

Last Posted Date: 2022-01-28

Lead Sponsor: National Cancer Center, Korea

Target Recruit Count: 128

Registration Number: NCT05213962

Locations: 🇰🇷
National Cancer Center Korea, Goyang, Gyeonggi, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy